SCHEMBL4438201

SCHEMBL4438201

Cc1ccc(C2(C(=O)CO)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
OPRM1 P35372 1/20 0.45
MAPT P10636 2/20 0.38
HTR1E P28566 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
S1PR3 Q99500 1/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP2C19 P33261 1/20 0.37
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2438762 0.85 HSD11B1 (0.49) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL4436038 0.81 APP (0.45) HSD11B1CYP3A4CYP2C9OPRM1MAPT
SCHEMBL5007609 0.81 HSD11B1 (0.53) HSD11B1OPRM1ALDH1A1SMN1; SMN2LMNA
SCHEMBL8353860 0.80 CYP2C9 (0.43) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL14347907 0.80 HSD11B1 (0.49) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL4555582 0.80 AKR1C1 (0.53) HSD11B1OPRM1NPSR1SMN1; SMN2LMNA
SCHEMBL351393 0.78 AKR1C1 (0.55) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL5379326 0.78 HSD11B1 (0.45) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL8351186 0.78 CYP3A4 (0.44) HSD11B1CYP3A4CYP2D6CYP2C9OPRM1
SCHEMBL4446502 0.77 THRB (0.50) OPRM1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE HSD11B1 3386/4885CYP3A4 2973/4885CYP2D6 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.